Direct Restriction of Virus Release and Incorporation of the Interferon-Induced Protein BST-2 into HIV-1 Particles

Investigation of the Vpu protein of HIV-1 recently uncovered a novel aspect of the mammalian innate response to enveloped viruses: retention of progeny virions on the surface of infected cells by the interferon-induced, transmembrane and GPI-anchored protein BST-2 (CD317; tetherin). BST-2 inhibits diverse families of enveloped viruses, but how it restricts viral release is unclear. Here, immuno-electron microscopic data indicate that BST-2 is positioned to directly retain nascent HIV virions on the plasma membrane of infected cells and is incorporated into virions. Virion-incorporation was confirmed by capture of infectivity using antibody to the ectodomain of BST-2. Consistent with a direct tethering mechanism, we confirmed that proteolysis releases restricted virions and further show that this removed the ectodomain of BST-2 from the cell surface. Unexpectedly, enzymatic cleavage of GPI anchors did not release restricted virions, weighing against models in which individual BST-2 molecules span the virion and host cell membranes. Although the exact molecular topology of restriction remains unsolved, we suggest that the incorporation of BST-2 into viral envelopes underlies its broad restrictive activity, whereas its relative exclusion from virions and sites of viral assembly by proteins such as HIV-1 Vpu may provide viral antagonism of restriction.

[1]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[2]  S. Neil,et al.  Antagonism to and Intracellular Sequestration of Human Tetherin by the Human Immunodeficiency Virus Type 2 Envelope Glycoprotein , 2009, Journal of Virology.

[3]  A. Sakurai,et al.  Dimerization of Tetherin Is Not Essential for Its Antiviral Activity against Lassa and Marburg Viruses , 2009, PloS one.

[4]  K. Strebel,et al.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu , 2009, Retrovirology.

[5]  L. Lanier,et al.  Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction , 2009, The Journal of experimental medicine.

[6]  R. Benarous,et al.  Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.

[7]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[8]  H. Kräusslich,et al.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. , 2009, Cell host & microbe.

[9]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[10]  K. Strebel,et al.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion , 2009, Proceedings of the National Academy of Sciences.

[11]  T. Noda,et al.  Inhibition of Lassa and Marburg Virus Production by Tetherin , 2008, Journal of Virology.

[12]  P. Bieniasz,et al.  Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin , 2008, Journal of Virology.

[13]  Michael Emerman,et al.  HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.

[14]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[15]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[16]  D. Richman,et al.  A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay. , 2006, Journal of virological methods.

[17]  A. McCormack,et al.  Quantitative Membrane Proteomics Reveals New Cellular Targets of Viral Immune Modulators , 2006, PLoS pathogens.

[18]  R. Schreiber,et al.  Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation1 , 2006, The Journal of Immunology.

[19]  Mark H Ellisman,et al.  Transform-based backprojection for volume reconstruction of large format electron microscope tilt series. , 2006, Journal of structural biology.

[20]  P. Bieniasz,et al.  HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane , 2006, PLoS pathogens.

[21]  Toshio Matsumoto,et al.  Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. , 2006, Oncology reports.

[22]  Thomas J Deerinck,et al.  Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots , 2005, Nature Methods.

[23]  J. Petriz,et al.  Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. , 2005, Cellular immunology.

[24]  G. Ruthel,et al.  In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Spearman,et al.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  George Banting,et al.  Bst‐2/HM1.24 Is a Raft‐Associated Apical Membrane Protein with an Unusual Topology , 2003, Traffic.

[27]  J. Lifson,et al.  Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation , 2001, Journal of Virology.

[28]  Dzung H. Nguyen,et al.  Evidence for Budding of Human Immunodeficiency Virus Type 1 Selectively from Glycolipid-Enriched Membrane Lipid Rafts , 2000, Journal of Virology.

[29]  M. Tsuchiya,et al.  Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. , 1999, Biochemical and biophysical research communications.

[30]  U. Schubert,et al.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains , 1996, Journal of virology.

[31]  J R Kremer,et al.  Computer visualization of three-dimensional image data using IMOD. , 1996, Journal of structural biology.

[32]  P. Charneau,et al.  Fusion from without directed by human immunodeficiency virus particles , 1994, Journal of virology.

[33]  R. Orentas,et al.  Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. , 1993, AIDS research and human retroviruses.

[34]  T. Klimkait,et al.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release , 1990, Journal of virology.

[35]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.